Clofarabine (CPB 0867, reviewed 2025-12-24)
Aetna considers clofarabine medically necessary for relapsed or refractory acute myeloid leukemia, for specified acute lymphoblastic leukemia indications including relapsed or refractory pediatric disease, for Langerhans cell histiocytosis in members 18 years of age or younger, and as conditioning for hematopoietic cell transplantation under the listed regimens. Continuation of clofarabine therapy is considered medically necessary when there is no evidence of unacceptable toxicity or disease progression on the current regimen. All other indications, including B-cell lymphoma, breast cancer, Ewing sarcoma and myelodysplastic syndrome, are considered experimental, investigational, or unproven.